Table 2. Breast cancer characteristics (a total of 2833 invasive breast cancer) by diabetes status identified from CMS data.
No diabetes (2534 patients) | Diabetes (299 patients) | P-valuea | |
---|---|---|---|
Stage | 0.001 | ||
Local | 1976 (78.0) | 216 (72.2) | |
Regional | 534 (21.1) | >=11 (∼) | |
Advanced | 24 (1.0) | <11 (∼) | |
Tumour size, mm | 0.13 | ||
≤5 | 319 (12.6) | 28 (9.4) | |
>5–10 | 691 (27.3) | 73 (24.4) | |
>10–20 | 822 (32.4) | 100 (33.4) | |
≥20 | 702 (27.7) | 98 (32.8) | |
Positive lymph nodes | 0.17 | ||
No | 1977 (78.0) | 219 (73.2) | |
Yes | 513 (20.2) | 73 (24.4) | |
Grade | 0.09 | ||
Well differentiated | 682 (26.9) | 71 (23.8) | |
Moderately differentiated | 1014 (40.0) | 144 (48.2) | |
Poorly differentiated | 567 (22.4) | 55 (18.4) | |
Anaplastic | 55 (2.2) | <11 (∼) | |
Missing | 216 (8.5) | >11 (∼) | |
OEstrogen receptor status | 0.75 | ||
Positive | 2042 (80.6) | 239 (79.9) | |
Negative | 346 (13.7) | 40 (13.4) | |
Borderline | <11 (∼) | <11 (∼) | |
Unknown/not done/missing | >11 (∼) | >11 (∼) | |
Progesterone receptor status | 0.66 | ||
Positive | 1736 (68.5) | 200 (66.9) | |
Negative | 640 (25.3) | 75 (25.1) | |
Borderline | 12 (0.5) | <11 (∼) | |
Unknown/not done/missing | 146 (5.8) | >11 (∼) | |
HER2 | 0.02 | ||
Positive | 300 (11.8) | 24 (8.0) | |
Negative | 1686 (66.5) | 229 (76.6) | |
Borderline | 20 (0.8) | <11 (∼) | |
Unknown/not done/missing | 528 (20.8) | >11 (∼) | |
Mammography interval | 0.02 | ||
<1 year | 1316 (51.9) | 132 (44.2) | |
1 to <2 years | 387 (15.3) | 48 (16.1) | |
2 to <5 years | 428 (16.9) | 71 (23.8) | |
5 or more years or never | 403 (15.9) | 48 (16.1) | |
Surgery | 0.10 | ||
No surgery | 118 (4.7) | 18 (6.0) | |
Breast conserving surgery (BCS) | 1648 (65.0) | 176 (58.9) | |
Mastectomy | 768 (30.3) | 105 (35.1) | |
Chemotherapy (yes) | 565 (22.3) | 72 (24.1) | 0.48 |
Radiation (yes) | 1486 (58.6) | 152 (50.8) | 0.01 |
(∼) The cell sizes were suppressed for confidentiality reasons per the Medicare data usage agreement.
χ2-test included missing category.